Supernus Pharmaceuticals IncNASDAQ:SUPN
- LAST PRICE29.3100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots28.0000/ 10
- Ask / Lots40.0000/ 4
- Open / Previous Close0.0000 / 29.3100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SUPN |
|---|---|---|
| 09:32 ET | 1430 | 30.01 |
| 09:34 ET | 300 | 30.02 |
| 09:36 ET | 1011 | 29.85 |
| 09:38 ET | 988 | 29.96 |
| 09:41 ET | 100 | 29.975 |
| 09:43 ET | 600 | 29.975 |
| 09:45 ET | 250 | 29.9483 |
| 09:48 ET | 600 | 29.895 |
| 09:50 ET | 600 | 29.7775 |
| 09:52 ET | 200 | 29.88 |
| 09:54 ET | 200 | 29.88 |
| 09:56 ET | 571 | 29.9 |
| 09:57 ET | 200 | 29.8725 |
| 09:59 ET | 100 | 29.88 |
| 10:01 ET | 1300 | 29.89 |
| 10:03 ET | 100 | 29.865 |
| 10:06 ET | 600 | 29.97 |
| 10:08 ET | 100 | 29.89 |
| 10:10 ET | 200 | 29.97 |
| 10:17 ET | 200 | 30.05 |
| 10:28 ET | 100 | 30.08 |
| 10:30 ET | 800 | 30.06 |
| 10:33 ET | 100 | 30.05 |
| 10:35 ET | 100 | 29.995 |
| 10:37 ET | 473 | 29.985 |
| 10:39 ET | 100 | 29.985 |
| 10:42 ET | 800 | 29.905 |
| 10:44 ET | 100 | 29.905 |
| 10:48 ET | 100 | 29.9 |
| 10:50 ET | 100 | 29.96 |
| 10:51 ET | 898 | 29.93 |
| 10:55 ET | 3649 | 29.89 |
| 10:57 ET | 100 | 29.89 |
| 11:00 ET | 100 | 29.89 |
| 11:02 ET | 400 | 29.94 |
| 11:06 ET | 200 | 29.89 |
| 11:08 ET | 100 | 29.88 |
| 11:13 ET | 999 | 29.79 |
| 11:15 ET | 17878 | 30.03 |
| 11:18 ET | 336 | 29.96 |
| 11:22 ET | 100 | 29.95 |
| 11:26 ET | 136 | 29.91 |
| 11:27 ET | 200 | 29.89 |
| 11:33 ET | 500 | 29.91 |
| 11:36 ET | 800 | 29.965 |
| 11:42 ET | 100 | 29.975 |
| 11:44 ET | 500 | 29.9 |
| 11:45 ET | 374 | 29.88 |
| 11:49 ET | 100 | 29.89 |
| 11:51 ET | 139 | 29.9434 |
| 11:56 ET | 100 | 29.95 |
| 11:58 ET | 119 | 30 |
| 12:00 ET | 100 | 29.9975 |
| 12:03 ET | 300 | 30.015 |
| 12:05 ET | 100 | 30.015 |
| 12:07 ET | 640 | 29.99 |
| 12:12 ET | 10793 | 29.9 |
| 12:14 ET | 400 | 29.85 |
| 12:18 ET | 200 | 29.79 |
| 12:20 ET | 100 | 29.74 |
| 12:21 ET | 600 | 29.78 |
| 12:27 ET | 807 | 29.79 |
| 12:30 ET | 822 | 29.8 |
| 12:36 ET | 400 | 29.745 |
| 12:38 ET | 200 | 29.72 |
| 12:48 ET | 100 | 29.63 |
| 12:52 ET | 100 | 29.6 |
| 12:54 ET | 300 | 29.69 |
| 12:56 ET | 200 | 29.635 |
| 12:57 ET | 665 | 29.695 |
| 12:59 ET | 1400 | 29.75 |
| 01:01 ET | 300 | 29.7 |
| 01:03 ET | 214 | 29.64 |
| 01:10 ET | 199 | 29.63 |
| 01:12 ET | 300 | 29.59 |
| 01:14 ET | 100 | 29.57 |
| 01:15 ET | 200 | 29.6 |
| 01:17 ET | 1056 | 29.6117 |
| 01:19 ET | 100 | 29.56 |
| 01:24 ET | 100 | 29.56 |
| 01:26 ET | 100 | 29.53 |
| 01:28 ET | 300 | 29.5 |
| 01:35 ET | 400 | 29.585 |
| 01:39 ET | 1893 | 29.51 |
| 01:44 ET | 803 | 29.5 |
| 01:46 ET | 300 | 29.51 |
| 01:51 ET | 100 | 29.5 |
| 01:55 ET | 100 | 29.58 |
| 01:57 ET | 500 | 29.53 |
| 02:00 ET | 100 | 29.53 |
| 02:02 ET | 200 | 29.5 |
| 02:04 ET | 100 | 29.49 |
| 02:08 ET | 7707 | 29.45 |
| 02:09 ET | 313 | 29.43 |
| 02:11 ET | 100 | 29.41 |
| 02:15 ET | 100 | 29.41 |
| 02:20 ET | 400 | 29.43 |
| 02:22 ET | 612 | 29.41 |
| 02:27 ET | 100 | 29.38 |
| 02:33 ET | 1002 | 29.33 |
| 02:36 ET | 314 | 29.29 |
| 02:38 ET | 100 | 29.27 |
| 02:42 ET | 900 | 29.29 |
| 02:49 ET | 200 | 29.25 |
| 02:51 ET | 400 | 29.26 |
| 02:54 ET | 200 | 29.29 |
| 02:56 ET | 200 | 29.2825 |
| 02:58 ET | 500 | 29.27 |
| 03:00 ET | 100 | 29.285 |
| 03:02 ET | 100 | 29.285 |
| 03:03 ET | 4200 | 29.335 |
| 03:05 ET | 1422 | 29.37 |
| 03:07 ET | 400 | 29.37 |
| 03:09 ET | 100 | 29.385 |
| 03:12 ET | 491 | 29.36 |
| 03:14 ET | 500 | 29.39 |
| 03:16 ET | 100 | 29.405 |
| 03:18 ET | 1013 | 29.3 |
| 03:20 ET | 1600 | 29.36 |
| 03:21 ET | 100 | 29.385 |
| 03:25 ET | 600 | 29.35 |
| 03:27 ET | 600 | 29.33 |
| 03:30 ET | 722 | 29.305 |
| 03:32 ET | 1083 | 29.25 |
| 03:34 ET | 33822 | 29.38 |
| 03:36 ET | 300 | 29.33 |
| 03:38 ET | 4768 | 29.32 |
| 03:39 ET | 2384 | 29.285 |
| 03:41 ET | 564 | 29.26 |
| 03:43 ET | 800 | 29.25 |
| 03:45 ET | 2412 | 29.24 |
| 03:48 ET | 13471 | 29.34 |
| 03:50 ET | 3670 | 29.17 |
| 03:52 ET | 2681 | 29.17 |
| 03:54 ET | 2393 | 29.27 |
| 03:56 ET | 7136 | 29.28 |
| 03:57 ET | 5296 | 29.3 |
| 03:59 ET | 68697 | 29.31 |
Apr 24, 2024
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024, from 4:05PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:05PM ET on Wednesday Apr 24, 2024 by Dow JonesSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN, from 3:17PM ET on Wednesday Apr 24, 2024 by Dow Jones
3:17PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 20, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN, from 11:00AM ET on Saturday Apr 20, 2024 by Dow Jones
11:00AM ET on Saturday Apr 20, 2024 by Dow Jones
Apr 18, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN, from 11:32AM ET on Thursday Apr 18, 2024 by Dow Jones
11:32AM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 8, 2024
DJ Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready, from 1:49PM ET on Monday Apr 08, 2024 by Dow Jones
1:49PM ET on Monday Apr 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Supernus Pharmaceuticals Inc | 1.6B | -1,930.8x | -59.02% |
Phibro Animal Health Corp | 503.9M | 34.0x | -13.61% |
Eagle Pharmaceuticals Inc | 55.1M | 4.7x | -4.75% |
PetIQ Inc | 484.9M | 265.9x | --- |
Medicine Man Technologies Inc | 50.6M | -0.4x | --- |
Shengtai Pharmaceutical Inc | 10.0 | 0.0x | --- |
Company Information
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Contact Information
- Headquarters
- 9715 Key West AvenueROCKVILLE, MD, United States 20850
- Phone
- 301-838-2500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Charles Newhall
- President, Chief Executive Officer, Secretary, Director
- Jack Khattar
- Chief Financial Officer, Senior Vice President
- Timothy Dec
- Senior Vice President - Intellectual Property, Chief Scientific Officer
- Padmanabh Bhatt
- Senior Vice President - Regulatory Affairs
- Tami Martin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $607.5M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.02 |
EPS | $-0.02 |
Book Value | $16.84 |
P/E Ratio | -1,930.8x |
Price/Sales (TTM) | 2.6 |
Price/Cash Flow (TTM) | 18.6x |
Operating Margin | -0.87% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
